LLY

784.16

-1.39%↓

JNJ

151.32

-1.29%↓

NVO

74.46

-0.01%↓

ABBV

186.37

-0.16%↓

UNH

309.25

+0.28%↑

LLY

784.16

-1.39%↓

JNJ

151.32

-1.29%↓

NVO

74.46

-0.01%↓

ABBV

186.37

-0.16%↓

UNH

309.25

+0.28%↑

LLY

784.16

-1.39%↓

JNJ

151.32

-1.29%↓

NVO

74.46

-0.01%↓

ABBV

186.37

-0.16%↓

UNH

309.25

+0.28%↑

LLY

784.16

-1.39%↓

JNJ

151.32

-1.29%↓

NVO

74.46

-0.01%↓

ABBV

186.37

-0.16%↓

UNH

309.25

+0.28%↑

LLY

784.16

-1.39%↓

JNJ

151.32

-1.29%↓

NVO

74.46

-0.01%↓

ABBV

186.37

-0.16%↓

UNH

309.25

+0.28%↑

Search

Cogent Biosciences Inc

Open

7.5 -0.92

Overview

Share price change

24h

Current

Min

7.34

Max

7.81

Key metrics

By Trading Economics

Income

-4.1M

-72M

EPS

-0.525

Employees

205

EBITDA

-1.2M

-74M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+133.05% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

172M

806M

Previous open

8.42

Previous close

7.5

Technical Score

By Trading Central

Confidence

Bearish Evidence

Cogent Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 cze 2025, 14:44 UTC

Acquisitions, Mergers, Takeovers

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17 cze 2025, 23:43 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17 cze 2025, 23:34 UTC

Market Talk

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Global Energy Roundup: Market Talk

17 cze 2025, 23:22 UTC

Market Talk

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17 cze 2025, 23:17 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17 cze 2025, 23:05 UTC

Market Talk

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17 cze 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

17 cze 2025, 22:58 UTC

Market Talk

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17 cze 2025, 22:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17 cze 2025, 22:31 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17 cze 2025, 22:14 UTC

Major Market Movers

Bitdeer Technologies Group Shares Fall on Note Offering

17 cze 2025, 19:49 UTC

Market Talk

Natural Gas Slow Down Gains -- Market Talk

17 cze 2025, 19:34 UTC

Market Talk

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17 cze 2025, 19:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 cze 2025, 19:10 UTC

Market Talk

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17 cze 2025, 18:41 UTC

Market Talk

Slowdown in US Consumer Spending Expected -- Market Talk

17 cze 2025, 18:15 UTC

Market Talk

Gold Inches Down as Profit-Taking Seen -- Market Talk

17 cze 2025, 17:44 UTC

Market Talk

Analysts Forecast Record-High Ethanol Output -- Market Talk

17 cze 2025, 16:37 UTC

Market Talk

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17 cze 2025, 16:30 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

17 cze 2025, 16:30 UTC

Market Talk

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

17 cze 2025, 16:15 UTC

Market Talk

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17 cze 2025, 16:12 UTC

Market Talk

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17 cze 2025, 14:54 UTC

Market Talk

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17 cze 2025, 14:47 UTC

Market Talk

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17 cze 2025, 14:41 UTC

Market Talk

Natural Gas Extends Climb -- Market Talk

17 cze 2025, 14:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Cogent Biosciences Inc Forecast

Price Target

By TipRanks

133.05% upside

12 Months Forecast

Average 16.5 USD  133.05%

High 25 USD

Low 7 USD

Based on 9 Wall Street analysts offering 12 month price targets forCogent Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

7

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

4.88 / 5.87Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Strong Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.